Senologie - Zeitschrift für Mammadiagnostik und -therapie 2020; 17(02): e9-e10
DOI: 10.1055/s-0040-1710622
Abstracts
Senologie

Platelet-rich plasma (PRP/ACP) in breast cancer patients Post-surgical complication rates and long term comparative analysis of the treatment 163 sentinel node biopsy patients

C Eichler
1  University of Cologne, Cologne, Germany, Department of Gynecology and Obstetrics, Köln, Deutschland
,
C Baucks
1  University of Cologne, Cologne, Germany, Department of Gynecology and Obstetrics, Köln, Deutschland
,
W Malter
1  University of Cologne, Cologne, Germany, Department of Gynecology and Obstetrics, Köln, Deutschland
,
F Thangarajah
1  University of Cologne, Cologne, Germany, Department of Gynecology and Obstetrics, Köln, Deutschland
,
J Puppe
1  University of Cologne, Cologne, Germany, Department of Gynecology and Obstetrics, Köln, Deutschland
,
J Holtschmidt
1  University of Cologne, Cologne, Germany, Department of Gynecology and Obstetrics, Köln, Deutschland
,
M Warm
1  University of Cologne, Cologne, Germany, Department of Gynecology and Obstetrics, Köln, Deutschland
2  Kliniken der Stadt Köln, Holweide, Brustzentrum, Köln, Deutschland
› Author Affiliations
 

Introduction Platelet rich plasma (PRP) is widely used in sports medicine, tissue repair and general surgery. Recent meta-analyses and prospective trials showed this product to be beneficial when introduced into a wound area.

Patients and methods Between the years 2015 and 2018, n = 163 patients received a sentinel node biopsy at the municipal hospital of Cologne, Holweide, Germany. The PRP product used was the Arthrex ACP® (autologous conditioned plasma) system. Patient recruitment was consecutive. Analysis was retrospective. The PRP product was introduced subcutaneously after wound closure. N=82 patients received an application of Arthrex ACP® compared to the control group n =  81. Primary endpoints were complication rate (seroma, revision, hematoma, infection); secondary endpoints were local, ipsilateral, contralateral and distant recurrence as well as any-cause of death at a median follow-up of 17 months.

Results Global complication rates did not differ significantly between both cohorts. There is a numerical, but non-significant advantage in seroma formation (2.4 % (ACP) vs. 3.7 % (control)). The same was shown for hematoma formation (0 %(ACP) vs. 3.7 % (control)). Surgical time did not increase with ACP application. Patient satisfaction was high. Secondary endpoint showed zero events for 17 month follow-up.

Conclusion This is the second long term retrospective analysis showing that PRP products such as Arthrex ACP® seem to be safe to use in oncological patients. In addition, this work is the first to demonstrate a slight benefit in a sentinel node biopsy setting for breast cancer patients.



Publication History

Publication Date:
24 June 2020 (online)

© Georg Thieme Verlag KG
Stuttgart · New York